With the new legislation by two dozen different federal lawmakers, and as well as Matt Gaetz and House Judiciary Chairman Bob Goodlatte, they have finally passed The Medical Cannabis Research Act of 2018. This law will assist in facilitating any clinical trials that are approved. These clinical trials will of course involved cannabis. With this law, there is no need for a manufacturer to secure a license. This also means that manufacturers can easily conduct clinical trials, not only for their benefits, but as well as for the public.
Another good thing about this law is that University of Mississippi, which is the sole marijuana provider, will have competitors. Especially that there are people who are complaining about the quality of their marijuana. To give you a clearer view, this article by Pail Armentano will tell you more about it:
Currently, the US National Institute on Drug Abuse designates the University of Mississippi to be the sole provider of marijuana for FDA-approved research. However, many of those familiar with their product have criticized its quality, opining that it possesses subpar potency, is often poorly manicured, and that it does not accurately reflect the wide variety of cannabis products and strains available to consumers.
Previous efforts to break this monopoly have so far been unsuccessful. In 2007, DEA Administrative Law Judge Mary Ellen Bittner determined that expanding the pool of federally licensed providers would be “in the public interest.” The agency ultimately rejected her decision. More recently, in 2016, the DEA changed its position and amended regulations in a manner to permit additional applicants to apply to federal licensure to grow marijuana. However, the Justice Department and the US Attorney General have thus far failed to take action on any pending applications. Continue reading here..
Hopefully, this will be a start of the wide medical marijuana use all over the world.